TBG Diagnostics Ltd TDL Product Pipeline Analysis 2018 Update Report Updated 26092018 Prices from USD $750

TBG Diagnostics Ltd TDL Product Pipeline Analysis, 2018 Update [Report Updated: 26092018] Prices from USD $750

04:50 EDT 23 Oct 2018 | BioPortfolio Reports

Summary


TBG Diagnostics Ltd TBG Diagnostics, formerly Progen Pharmaceuticals Ltd, is a molecular diagnostics company that develops, manufactures and markets molecular diagnostics kits, instruments and services. The company's major products include nucleic acid extraction kits, HLA SBT typing kits, HPA genotyping kits, automated pipetting system, and gel electrophoresis. It serves clinical laboratories of hospitals and independent reference labs, blood centers and bone marrow registry labs worldwide. It has research and development RD facilities in the US, Taiwan and China and a manufacturing facility in Xiamen, China. The company has collaboration and product licensing agreements with various pharmaceutical companies and others to expand market presence and product portfolio. TBG Diagnostics is headquartered in Greenslopes, Queensland, Australia.


This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


Scope:


The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company TBG Diagnostics Ltd

The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to Buy:


Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research Development strategies

Develop marketentry and market expansion strategies

Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

More From BioPortfolio on "TBG Diagnostics Ltd TDL Product Pipeline Analysis, 2018 Update [Report Updated: 26092018] Prices from USD $750"